Citigroup
ADCT icon

Citigroup’s ADC Therapeutics ADCT Stock Holding History

Citigroup’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$119K Buy
31,670
+15,561
+97% +$61.3K ﹤0.01% 4216
2025
Q4 		$56.9K Buy
16,109
+12,665
+368% +$51.4K ﹤0.01% 4522
2025
Q3 		$13.8K Sell
3,444
-22,646
-87% -$71.4K ﹤0.01% 4929
2025
Q2 		$69.9K Sell
26,090
-31,556
-55% -$66.4K ﹤0.01% 4591
2025
Q1 		$81.3K Sell
57,646
-6,493
-10% -$11K ﹤0.01% 4705
2024
Q4 		$128K Buy
64,139
+5,237
+9% +$13.7K ﹤0.01% 4703
2024
Q3 		$186K Buy
58,902
+43,479
+282% +$137K ﹤0.01% 4389
2024
Q2 		$48.7K Buy
+15,423
New +$61.3K ﹤0.01% 4596
2023
Q3 		– Sell
-1,834
Closed -$3.94K – 5653
2023
Q2 		$3.94K Buy
+1,834
New +$4.12K ﹤0.01% 5209
2023
Q1 		– Sell
-38
Closed -$146 – 5450
2022
Q4 		$146 Buy
38
+7
+23% +$28 ﹤0.01% 5619
2022
Q3 		$0 Sell
31
-2
-6% -$14 ﹤0.01% 5775
2022
Q2 		$0 Hold
33
– – ﹤0.01% 6186
2022
Q1 		$0 Buy
33
+1
+3% +$16 ﹤0.01% 6273
2021
Q4 		$1K Buy
+32
New +$772 ﹤0.01% 5749

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup's ADCT Position: Q1 2026 in Review

Citigroup increased its ADC Therapeutics (ADCT) stake by 97% in Q1 2026, buying an estimated $61.3K and bringing the position to 31,670 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #4216.

Citigroup first reported a position in ADCT in Q4 2021 and has held it in 14 quarters since. The position peaked at $186K in Q3 2024. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Citigroup held 31,670 shares of ADC Therapeutics worth $119K as of Q1 2026.
  • Citigroup bought 15,561 ADC Therapeutics shares in Q1 2026, an estimated $61.3K.
  • ADC Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4216 holding.
  • Citigroup first reported a position in ADC Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Citigroup's ADC Therapeutics position peaked at $186K in Q3 2024.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.